Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01989949 · ClinicalTrials.gov registry record · Phase 1
Safety and Pharmacokinetic (PK) Study to Assess Bronchopulmonary Disposition of IV Eravacycline (TP-434) in Healthy Men and Women
A Phase 1 study, sponsored by Tetraphase Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT01989949 is a Phase 1 study that has completed, run by Tetraphase Pharmaceuticals. The registered enrollment target is 20 participants.
The verdict
NCT01989949, a Phase 1 study, has completed, sponsored by Tetraphase Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is a phase 1, open-label, randomized pharmacokinetic and safety study in healthy adult subjects, who will undergo bronchoscopy and bronchoalveolar lavage (BAL) after receiving seven (7) doses of 1.0 mg/kg IV TP-434.
Interventions
- DRUG TP-434 (Eravacycline) reconstituted and administered via an IV infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2012-11 |
| Est. Completion | 2013-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01989949
The ClinicalTrials.gov registry entry for NCT01989949 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tetraphase Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TP-434 (Eravacycline) reconstituted and administered via an IV infusion is the first listed.
NCT01989949 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01989949 about?
NCT01989949 is a clinical study titled "Safety and Pharmacokinetic (PK) Study to Assess Bronchopulmonary Disposition of IV Eravacycline (TP-434) in Healthy Men and Women". This is a phase 1, open-label, randomized pharmacokinetic and safety study in healthy adult subjects, who will undergo bronchoscopy and bronchoalveolar lavage (BAL) after receiving seven (7) doses of 1.0 mg/kg IV TP-434.
What is the current status of trial NCT01989949?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2012-11. Estimated completion is 2013-04.
What interventions are being tested in trial NCT01989949?
The interventions under investigation include: TP-434 (Eravacycline) reconstituted and administered via an IV infusion (DRUG).
Who is sponsoring clinical trial NCT01989949?
This trial is sponsored by Tetraphase Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.